Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 3 Study of Selpercatinib in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

For more information:

https://clinicaltrials.gov/ct2/show/NCT04819100?cond=A+Placebo-controlled+Double-Blinded+Randomized+Phase+3+Study+of+Adjuvant+Selpercatinib+following+Definitive+Locoregional+Treatment+in+Participants+with+Stage+IB-IIIA+RET+fusion-Positive+NSCLC&draw=2&rank=1